Mark P Marriott
Overview
Explore the profile of Mark P Marriott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clarke L, Bukhari W, OGorman C, Khalilidehkordi E, Arnett S, Woodhall M, et al.
Mult Scler Relat Disord
. 2022 Feb;
58:103408.
PMID: 35216788
Background: Neuromyelitis optica spectrum disorder (NMOSD) is associated with significant morbidity and mortality. Several therapies have been recommended for NMOSD and more recently clinical trials have demonstrated efficacy for three...
2.
Clarke L, Arnett S, Bukhari W, Khalilidehkordi E, Sanchez S, OGorman C, et al.
Front Neurol
. 2021 Sep;
12:722237.
PMID: 34566866
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the CNS. Overlap in the clinical and MRI features of NMOSD and MS means that distinguishing these...
3.
Seery N, Sharmin S, Li V, Nguyen A, Meaton C, Atvars R, et al.
CNS Drugs
. 2021 Apr;
35(8):907-918.
PMID: 33847902
Background: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label extension (OLE) studies. However, risk factors for infection in patients with multiple sclerosis (MS) receiving ocrelizumab have...
4.
Seery N, Li V, Nguyen A, Roos I, Buzzard K, Atvars R, et al.
Mult Scler Relat Disord
. 2020 Sep;
46:102516.
PMID: 32957057
Objective: Patients with Multiple Sclerosis (MS) and on disease modifying therapies (DMTs) that can be immunosuppressive or immunomodulatory form a special group where risk of continuation of DMT needs to...
5.
Khalilidehkordi E, Clarke L, Arnett S, Bukhari W, Sanchez S, OGorman C, et al.
Front Neurol
. 2020 Jul;
11:537.
PMID: 32612571
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) show overlap in their clinical features. We performed an analysis of relapses with the aim of determining differences between the two...
6.
Bukhari W, Clarke L, OGorman C, Khalilidehkordi E, Arnett S, Prain K, et al.
J Neurol
. 2020 Feb;
267(5):1431-1443.
PMID: 32006158
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and...
7.
Bukhari W, Prain K, Waters P, Woodhall M, OGorman C, Clarke L, et al.
J Neurol Neurosurg Psychiatry
. 2017 May;
88(8):632-638.
PMID: 28550069
Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of...
8.
Steinhubl S, Marriott M, Wegerich S
Glob Health Sci Pract
. 2015 Sep;
3(3):516-9.
PMID: 26374808
No abstract available.
9.
Gresle M, Butzkueven H, Perreau V, Jonas A, Xiao J, Thiem S, et al.
Glia
. 2015 Feb;
63(6):1005-20.
PMID: 25639936
In order to further investigate the molecular mechanisms that regulate oligodendrocyte (OC) survival, we utilized microarrays to characterize changes in OC gene expression after exposure to the cytokines neurotrophin3, insulin,...
10.
Marriott M, Emery B, Cate H, Binder M, Kemper D, Wu Q, et al.
Glia
. 2008 Feb;
56(6):686-98.
PMID: 18293407
Leukemia inhibitory factor (LIF) receptor signaling limits the severity of inflammatory demyelination in experimental autoimmune encephalomyelitis, a T-cell dependent animal model of multiple sclerosis (MS) [Butzkueven et al. (2002) Nat...